NCT05088889 2023-11-28Maintenance Ipilimumab + Nivolumab Post Induction Chemotherapy + SBRT for First Line Treatment Stage IV Pancreatic CancerSheba Medical CenterPhase 1 Unknown10 enrolled
NCT03166397 2023-01-26Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma PatientsSheba Medical CenterPhase 2 Recruiting30 enrolled
NCT02982486 2017-11-01A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial CarcinomaAssaf-Harofeh Medical CenterPhase 2 Unknown60 enrolled